Skip to main content
. 2022 Dec 1;11(6):210–215. doi: 10.14740/jh1062

Figure 1.

Figure 1

Longitudinal incidence of new SARS-CoV-2 infections in the cohort of patients with hematological malignancy who received Evusheld versus the local community. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.